FDA

Quelicin

Approved 1 May 1953InjectionInjectable

Indications

QUELICIN is indicated in adults and pediatric patients:

as an adjunct to general anesthesia
to facilitate tracheal intubation
to provide skeletal muscle relaxation during surgery or mechanical ventilation. QUELICIN is a depolarizing neuromuscular blocker indicated in adults and pediatric patients:
as an adjunct to general anesthesia ( 1 )
to facilitate tracheal intubation ( 1 )
to provide skeletal muscle relaxation during surgery or mechanical ventilation. ( 1 )

QUELICIN is contraindicated:

in patients with skeletal muscle myopathies [see Warnings and Precautions (5.1) ]
in patients with known hypersensitivity to succinylcholine. Severe anaphylactic reactions to succinylcholine have been reported [see Warnings and Precautions (5.2) ]
after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, which may result in severe hyperkalemia and cardiac arrest [see Warnings and Precautions (5.4) ]
in patients with known or suspected genetic susceptibility to malignant hyperthermia [see Warnings and Precautions (5.5) , Clinical Pharmacology (12.5) ]
Skeletal muscle myopathies ( 4 )
Known hypersensitivity to succinylcholine ( 4 )
After the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury ( 4 )
Known or suspected genetic susceptibility to malignant hyperthermia ( 4 )

Anaphylaxis : Severe anaphylactic reactions to neuromuscular blocking agents, including succinylcholine, have been reported. Some cases have been life-threatening and fatal. Take necessary precautions, such as the immediate availability of appropriate emergency treatment. ( 5.2 )
Risk of Death due to Medication Errors : Unintended administration of QUELICIN may result in paralysis, respiratory arrest and death. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings. ( 5.3 )
Hyperkalemia : QUELICIN may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia. ( 5.4 )

Indications

QUELICIN is indicated in adults and pediatric patients:

as an adjunct to general anesthesia
to facilitate tracheal intubation
to provide skeletal muscle relaxation during surgery or mechanical ventilation. QUELICIN is a depolarizing neuromuscular blocker indicated in adults and pediatric patients:
as an adjunct to general anesthesia ( 1 )
to facilitate tracheal intubation ( 1 )
to provide skeletal muscle relaxation during surgery or mechanical ventilation. ( 1 )

Contraindications

QUELICIN is contraindicated:

in patients with skeletal muscle myopathies [see Warnings and Precautions (5.1) ]
in patients with known hypersensitivity to succinylcholine. Severe anaphylactic reactions to succinylcholine have been reported [see Warnings and Precautions (5.2) ]
after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, which may result in severe hyperkalemia and cardiac arrest [see Warnings and Precautions (5.4) ]
in patients with known or suspected genetic susceptibility to malignant hyperthermia [see Warnings and Precautions (5.5) , Clinical Pharmacology (12.5) ]
Skeletal muscle myopathies ( 4 )
Known hypersensitivity to succinylcholine ( 4 )
After the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury ( 4 )
Known or suspected genetic susceptibility to malignant hyperthermia ( 4 )

Warnings and precautions

Anaphylaxis : Severe anaphylactic reactions to neuromuscular blocking agents, including succinylcholine, have been reported. Some cases have been life-threatening and fatal. Take necessary precautions, such as the immediate availability of appropriate emergency treatment. ( 5.2 )
Risk of Death due to Medication Errors : Unintended administration of QUELICIN may result in paralysis, respiratory arrest and death. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings. ( 5.3 )
Hyperkalemia : QUELICIN may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia. ( 5.4 )